These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34712242)

  • 41. Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa.
    Sakae Y; Satoh T; Yagi H; Yanaka S; Yamaguchi T; Isoda Y; Iida S; Okamoto Y; Kato K
    Sci Rep; 2017 Oct; 7(1):13780. PubMed ID: 29062024
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.
    Edwards JM; Heydarchi B; Khoury G; Salazar-Quiroz NA; Gonelli CA; Wines B; Hogarth PM; Kristensen AB; Parsons MS; Purcell DFJ
    J Virol; 2021 Jun; 95(13):e0021921. PubMed ID: 33853957
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.
    Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W
    J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fc gamma receptor glycosylation modulates the binding of IgG glycoforms: a requirement for stable antibody interactions.
    Hayes JM; Frostell A; Cosgrave EF; Struwe WB; Potter O; Davey GP; Karlsson R; Anneren C; Rudd PM
    J Proteome Res; 2014 Dec; 13(12):5471-85. PubMed ID: 25345863
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Functional diversification of IgGs through Fc glycosylation.
    Wang TT; Ravetch JV
    J Clin Invest; 2019 Sep; 129(9):3492-3498. PubMed ID: 31478910
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.
    Li W; Zhu Z; Chen W; Feng Y; Dimitrov DS
    Front Immunol; 2017; 8():1554. PubMed ID: 29181010
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
    Isoda Y; Yagi H; Satoh T; Shibata-Koyama M; Masuda K; Satoh M; Kato K; Iida S
    PLoS One; 2015; 10(10):e0140120. PubMed ID: 26444434
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of Fc Gamma Receptor Glycoforms That Produce Differential Binding Kinetics for Rituximab.
    Hayes JM; Frostell A; Karlsson R; Müller S; Martín SM; Pauers M; Reuss F; Cosgrave EF; Anneren C; Davey GP; Rudd PM
    Mol Cell Proteomics; 2017 Oct; 16(10):1770-1788. PubMed ID: 28576848
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies.
    Yoon HW; Jo M; Ko S; Kwon HS; Lim CS; Ko BJ; Lee JC; Jung ST
    Mol Immunol; 2019 Oct; 114():62-71. PubMed ID: 31336250
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms.
    Ferrara C; Stuart F; Sondermann P; Brünker P; Umaña P
    J Biol Chem; 2006 Feb; 281(8):5032-6. PubMed ID: 16330541
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry.
    Woodall DW; Dillon TM; Kalenian K; Padaki R; Kuhns S; Semin DJ; Bondarenko PV
    MAbs; 2022; 14(1):2004982. PubMed ID: 34978527
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report.
    Kumpel BM; Beliard R; Brossard Y; Edelman L; de Haas M; Jackson DJ; Kooyman P; Ligthart PC; Monchâtre E; Overbeeke MA; Puillandre P; de Romeuf C; Wilkes AM
    Transfus Clin Biol; 2002 Jan; 9(1):45-53. PubMed ID: 11889899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms.
    Mimura Y; Church S; Ghirlando R; Ashton PR; Dong S; Goodall M; Lund J; Jefferis R
    Mol Immunol; 2000; 37(12-13):697-706. PubMed ID: 11275255
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques.
    Shubin Z; Li W; Poonia B; Ferrari G; LaBranche C; Montefiori D; Zhu X; Pauza CD
    Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28404572
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Engineering IgG1 Fc Domains That Activate the Complement System.
    Lee CH; Delidakis G
    Methods Mol Biol; 2022; 2421():187-200. PubMed ID: 34870820
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Binding affinities of human IgG1 and chimerized pig and rabbit derivatives to human, pig and rabbit Fc gamma receptor IIIA.
    Bhatti MM; Cai AG; Theunissen JW
    PLoS One; 2019; 14(7):e0219999. PubMed ID: 31323052
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low pH Exposure During Immunoglobulin G Purification Methods Results in Aggregates That Avidly Bind Fcγ Receptors: Implications for Measuring Fc Dependent Antibody Functions.
    Lopez E; Scott NE; Wines BD; Hogarth PM; Wheatley AK; Kent SJ; Chung AW
    Front Immunol; 2019; 10():2415. PubMed ID: 31681303
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural mechanism of high affinity FcγRI recognition of immunoglobulin G.
    Lu J; Sun PD
    Immunol Rev; 2015 Nov; 268(1):192-200. PubMed ID: 26497521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity.
    Zhang Q; Joubert MK; Polozova A; De Guzman R; Lakamsani K; Kinderman F; Xiang D; Shami A; Miscalichi N; Flynn GC; Kuhns S
    Biotechnol Prog; 2020 Nov; 36(6):e3045. PubMed ID: 32627435
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Site-Selective Chemoenzymatic Modification on the Core Fucose of an Antibody Enhances Its Fcγ Receptor Affinity and ADCC Activity.
    Li C; Chong G; Zong G; Knorr DA; Bournazos S; Aytenfisu AH; Henry GK; Ravetch JV; MacKerell AD; Wang LX
    J Am Chem Soc; 2021 May; 143(20):7828-7838. PubMed ID: 33977722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.